Drug-Resistant Malaria - libdoc.who.int - World Health Organization

More documents

Recommendations

Info

112 / APPENDICES 0.25 0.50 0.75 1.00 1.5 2.0 76 - 4 51 - 75 9 1 1 26 - 50 3 4 1 1 1 - 25 1 12 8 5 2 2 0 8 11 14 15 The shapes of the two distributions can be compared 1n a simple way by multiplying each figure 1n the second table by 5; this yie lds the figures 1n brackets in the first table. The two distributions are remarkably similar.
APPENDIX 5 Antimalarial Drugs and Drug Regimens (Falciparum Malaria) 1. MEDICAMENTS FOR THE TREATMENT OF UNCOMPLICATED FALCIPARUM MALARIA 1.1 Chloroquine 7-chloro-4-(4'-diethylamino-1'-methy1butylamino) quinoline Trade names: Regimen: Phosphate salts - Aralen, Avloclor, Arechin, Arquin, Baraquine, Fetoquin, Chinophen, Kalquin, Clorkin, Kwinema1, Delagil, Lagaquin, Diroquine, Malarex, Malarivon, Mexaquin, Quinalen, Quinora, Resochin. Rivoquine, Roquin, Siragan, Teraquin. Sulfate salt - Nivaquine Formulat ions available: Tablet s of 150 mg and 300 mg base. Syrups of various strengths. Adults l - 600 mg 2 (base) initially then 600 mg at 24 hours and 300 mg 48 hours later 1 Adult is defined as a person of 60 kg body weight or over. 2 In some areas, 2.4 g base over 4-5 days have been used.
Page 1:
Drug-Resistant Malaria The Report o
Page 5:
Foreword A meeting on drug-resistan
Page 8 and 9:
CONTENTS Page Drug Pressure and Res
Page 10 and 11:
2 / INTRODUCTION Differences in dru
Page 13 and 14:
II. Opening Address and Messages Ol
Page 15 and 16:
OPENING ADDRESS / 7 phical boundari
Page 17 and 18:
OPENING ADDRESS / 9 to preserve for
Page 19 and 20:
OPENING ADDRESS / 11 is also here a
Page 21 and 22:
Ill. Review of Drug Resistance in P
Page 23 and 24:
REVIEW I 15 Table 1. Sensitivity Te
Page 25 and 26:
REVIEW / 17 Other Studies Validatio
Page 27 and 28:
Distribution of Chloroquine-Resista
Page 29 and 30:
REVIEW I 21 are signs to suggest th
Page 31 and 32:
REVIEW / 23 (h) specialized investi
Page 33 and 34:
REVIEW / 25 TABLE 3~ Comparison of
Page 35 and 36:
REVIEW / 27 Of 22 mefloquine in vit
Page 37 and 38:
REVIEW / 29 operational conditions
Page 39 and 40:
REVIEW / 31 the possible influence
Page 41 and 42:
IV. Monitoring of Drug Response of
Page 43 and 44:
MONITORING / 35 during recent years
Page 45 and 46:
MONITORING / 37 India, Sri Lanka an
Page 47 and 48:
Table 4. Results of Micro In Vitro
Page 49 and 50:
MONITORING / 41 The superiority of
Page 51 and 52:
MONITORING / 43 input of the result
Page 53 and 54:
MONITORING / 45 table time 1ag and
Page 55 and 56:
Table 6. Probability of Detecting t
Page 57 and 58:
MONITORING / 49 prevalence = 10% an
Page 59:
MONITORING / 51 TDR. At the end of
Page 62 and 63:
54 / RESEARCH RESULTS characteristi
Page 64 and 65:
56 / RESEARCH RESULTS EXO-ERYTHROCY
Page 67 and 68:
VI. Control of Drug-Resistant P. fa
Page 69 and 70: CONTROL / 61 DRUG USE AIMING AT PRE
Page 71 and 72: Table 7. Specific Actions for the C
Page 73 and 74: CONTROL / 65 Table 8. Drugs or Comb
Page 75 and 76: Table 9. Suggested Use of Antimalar
Page 77 and 78: Table 9. Suggested Use of Antimalar
Page 79 and 80: CONTROL / 71 Radical therapy of mic
Page 81 and 82: CONTROL / 73 Tanzania several years
Page 83 and 84: VII. Field and Laboratory Research
Page 85 and 86: RESEARCH FOR CONTROL / 77 In vivo a
Page 87 and 88: RESEARCH FOR CONTROL / 79 migrants
Page 89 and 90: RESEARCH FOR CONTROL / 81 and Phase
Page 91: RESEARCH FOR CONTROL / 83 (b) Metho
Page 94 and 95: 86 / RECOMMENDATIONS and sulfonamid
Page 96 and 97: 88 / RECOMMENDATIONS (xiii) Simple
Page 99 and 100: IX. Summary The Meeting on Drug-Res
Page 101 and 102: APPENDIX 1 List of Participants, Ob
Page 103 and 104: APPENDICES / 95 Sri Lanka Dr M.K. B
Page 105 and 106: APPENDICES / 97 Papua New Guinea Dr
Page 107 and 108: APPENDICES / 99 TEMPORARY ADVISERS
Page 109 and 110: APPENDICES / 101 Dr L.E. Molineaux
Page 111 and 112: APPENDIX 2 List of Documents A. WOR
Page 113 and 114: APPENDICES / 105 Comparative study
Page 115 and 116: APPENDIX 3.1 I 107 RESPONSE OF Plas
Page 117: APPENDIX 3.2 / 109 RESPONSE OF P. F
Page 122 and 123: 114 / APPENDICES Chloroquine is eff
Page 124 and 125: 116 / APPENDICES 1.4 Sulfonamide pl
Page 126 and 127: 118 / Various tetracycline analogs
Page 128 and 129: 120 / APPENDICES A loading dose on
Page 130 and 131: 122 / APPENDICES The drug should be
Page 132 and 133: 124 / APPEND ICE S 2. INDICATIONS f
Page 134 and 135: 126 / APPENDICES they are already r
Page 136 and 137: 128 / APPENDICES 5.2 In suppressive
Page 138 and 139: 130 / APPENDICES Outline research p
Page 140 and 141: 132 / APPENDICES Long-term To preve
Page 143 and 144: APPENDIX 8 Considerations Related t
Page 145 and 146: APPENDICES / 137 4. Screening point
show all

Drug-Resistant Malaria - libdoc.who.int - World Health Organization

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?